Investigating the Bioavailability of Broccoli Extract Supplements

NCT07564674 | Not Yet Recruiting

• 1 other identifier: LPI-2026-2211
• Study Type: interventional
• Target: 12
• Locations: 0 countries
• Sites: N/A

Brief Summary

The goal of this clinical trial is to compare how much glucoraphanin and sulforaphane from 3 different versions of broccoli extract supplements is absorbed into the body and excreted in urine. This study involves generally healthy adults age 18-60 years. The supplements contain glucoraphanin and myrosinase enzyme, both naturally occurring in cruciferous vegetables. Once ingested, glucoraphanin is converted to the bioactive compound sulforaphane, which is thought to have numerous health benefits, including cancer prevention. Participants will:

• consume 3 different versions of broccoli extract supplements (glucoraphanin will range from 35-70 mg)
• complete 3 separate 24 hour study cycles
• submit blood and urine samples for 24 hours
• follow diet restrictions (no cruciferous vegetables or condiments or phytochemical/herbal supplements for 1 week prior to and during each study cycle)

Conditions

Diet, Healthy

Keywords

cruciferous vegetable; broccoli extract supplement; glucoraphanin; sulforaphane

Outcome Measures

Primary Outcomes (5)

• Urine sulforaphane

  Change from baseline levels of sulforaphane in urine

  0, 2, 4, 8, and 24 hours

• Urine sulforaphane metabolites

  Change from baseline levels of sulforaphane in urine

  0, 2, 4, 8, and 24 hours

• Plasma glucoraphanin

  Change from baseline levels of plasma glucoraphanin

  0, 1, 2, 4, 8, and 24 hours

• Plasma sulforaphane

  Change from baseline levels of plasma sulforaphane

  0, 1, 2, 4, 8, and 24 hours

• Plasma sulforaphane metabolites

  Change from baseline levels of plasma sulforaphane metabolites

  0, 1, 2, 4, 8, and 24 hours

Study Arms (3)

35 mg glucoraphanin

ACTIVE COMPARATOR

Participants will swallow by mouth 1 tablet of Avmacol Extra Strength with coating.

Dietary Supplement: Avmacol Extra Strength with coating - 1 tablet

60 mg glucoraphanin

ACTIVE COMPARATOR

Participants will chew and swallow by mouth 2 tablets of Avmacol chewable wafers (30 mg glucoraphanin each)

Dietary Supplement: Avmacol chewable wafer - 2 tablets

70 mg glucoraphanin

ACTIVE COMPARATOR

Participants will swallow by mouth 2 tablets of Avmacol Extra Strength with coating (35 mg glucoraphanin each)

Dietary Supplement: Avmacol Extra Strength with coating - 2 tablets

Interventions

Avmacol Extra Strength with coating - 1 tablet DIETARY_SUPPLEMENT

Participants will swallow by mouth 1 tablet Avamacol Extra Strength with coating (35 mg glucoraphanin per tablet)

35 mg glucoraphanin

Avmacol chewable wafer - 2 tablets DIETARY_SUPPLEMENT

Participants will chew and swallow by mouth 2 wafers Avmacol chewable wafers (30 mg glucoraphanin per wafer)

60 mg glucoraphanin

Avmacol Extra Strength with coating - 2 tablets DIETARY_SUPPLEMENT

Participants will swallow by mouth 2 tablets Avamacol Extra Strength with coating (35 mg glucoraphanin per tablet)

70 mg glucoraphanin

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy adults, 18-60 years of age
• Willing to stop taking herbal and phytochemical (plant-based extract or phytochemical) supplements for 1 week prior to and during each study cycle
• Willing to stop cruciferous vegetable intake 1 week prior to and during each study cycle
• Must be able to give written informed consent

You may not qualify if:

• Body Mass Index (BMI) \<18.5 or \>30.0 kg/m2
• Tobacco use, including e-cigarettes, or smoking of any substance (e.g. cannabis) in the past three months
• Pregnancy, breastfeeding, or planning to become pregnant before completing the study
• Engaging in vigorous exercise more than 7 hours per week
• Have a significant acute or chronic illness such as cardiovascular disease, kidney or liver disease, diabetes, thyroid disorder, or radiation or chemotherapy treatment for cancer within the past five years
• Use of medications to control cholesterol (e.g. statins, cholestyramine) or fat absorption (e.g. orlistat)
• Have had bariatric surgery (e.g. gastric bypass, gastric banding, sleeve gastrectomy, etc.), other gastrointestinal procedure (e.g. cholecystectomy) or disorders (e.g. Crohn's disease, celiac disease, ulcerative colitis)
• Allergic to broccoli, moringa, mustard, or maitake mushrooms
• Weighs less than 110 pounds
• Diagnosis of sickle cell disease

Sponsors & Collaborators

• Oregon State University: lead

Study Officials

• Emily Ho, PhD

  Oregon State University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Emily Ho, PhD

CONTACT

541-737-9559; emily.ho@oregonstate.edu

Sandra Uesugi, RN, BSN, MS

CONTACT

541-737-3594; sandra.uesugi@oregonstate.edu

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Masking Details: Participants will be blinded to the dose of glucoraphanin in each arm. Study staff analyzing samples will be blinded to treatment group.
• Purpose: BASIC SCIENCE
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 27, 2026
• First Posted: May 4, 2026
• Study Start (Estimated): September 1, 2026
• Primary Completion (Estimated): September 1, 2027
• Study Completion (Estimated): September 1, 2028
• Last Updated: May 4, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share